1/31
Looks like no tags are added yet.
Understand the pharmacology of estrogen receptors
(Receptor type, activation, effects)
Estrogen receptors (ER)
Nuclear receptor superfamily.
There are 2 subtypes: ERα and ERβ.
ERα and ERβ have different tissue distributions.
Mechanism of estrogen receptor activation
Estrogen enters cell cell by passive diffusion through plasma membrane → binds to the estrogen receptor (ER) → dimerization of ERs → cofactor recruitment → ER dimer–cofactor complex binds to DNA → gene expression.
Effects of estrogen receptor activation on:
Uterus, breast tissue, urogenital tract, bone, liver
Estrogen has negative feedback on the hypothalamus/pituitary → decreases FSH and LH.
Explain the mechanism of action of combined & progestins only hormonal.
Combined:
Estrogen: Inhibits ovulation
Progestin: Thickens cervical mucus
Progestin-Only Contraceptives
Mechanisms:
Thickening of cervical mucus
Atrophy of the endometrium
Hindering implantation
Interfere with tubal transport of ova
Key Structural Features of Estrogen Derivatives
Most CHCs contain either:
Ethinyl estradiol
Estradiol
Important structural/pharmacokinetic features
Ethyne substitution at position 17:
↓ Hepatic metabolism
↑ Bioavailability
Estradiol valerate:
Metabolized to estradiol
Mestranol:
Metabolized to ethinyl estradiol
Estetrol:
Fetal estrogen
Lower potency than estradiol
Better oral bioavailability
Less plasma protein binding
Longer half-life compared with estradiol
Has a SERM-like profile with antagonist effects in breast tissue and agonist effects in other tissues
Key Structural Features of Progestin Derivatives
Generation | Examples | Androgenic activity |
|---|---|---|
1st (Estranes) | Norethindrone, norethindrone acetate, ethynodiol diacetate | High |
2nd (Gonanes) | Levonorgestrel, norgestrel | Moderate |
3rd (Newer gonanes) | Desogestrel, etonogestrel, norgestimate | No |
4th | Drospirenone, spironolactone | Anti-androgenic |
Estrane progestins:
Structurally similar to testosterone
This contributes to their androgenic activity
Have:
A keto group at position 3
A methyl group at position 17
Desogestrel:
Rapidly metabolized in the gut wall and liver to etonogestrel
Norgestimate:
Metabolized in the gut and liver to norelgestromin
Drospirenone:
Progesterone receptor agonist
Testosterone receptor antagonist
CHC: Combined Oral Contraceptives (COCs)
(Ingredients, schedule, formulations)
Contain:
Estrogen
Progestin
Typically taken:
21 days of active pills
7 days of placebo or no pill
Formulations:
Monophasic: fixed estrogen and progestin dose
Biphasic: dose increased once during the cycle
Triphasic: dose increased twice during the cycle
Recently tetraphasic formulations advantage and limitations.
CHC: Transdermal Patch
(Ingredients, schedule, advantages, limitations)
Contains:
Ethinyl estradiol
Norelgestromin
Schedule:
3 weeks on / 1 week off
Advantages:
Better compliance
Limitations:
60% higher dose of estrogen than COCs
Possible higher risk of VTE
Subcutaneous fat may interfere with absorption
Not recommended for individuals >90 kg
Cost
Vaginal Ring
(Ingredients, schedule, advantages, limitations)
Contains:
Ethinyl estradiol
Etonogestrel
Schedule:
3 weeks on / 1 week off
Advantage:
Better compliance
Limitations:
Comfort level with insertion may be a concern
Cost
Progestin Only Pills
(Characteristics, limitation)
Characteristics:
No estrogen
Lower dose of progestin than COCs
No break or placebo pills
Light or no menstruation
Spotting possible
Major limitation:
Compliance is critical
Must be taken at the same time daily
Progestin Only Pills
(Characteristics, Limitation)
Characteristics:
No estrogen
Lower dose of progestin than COCs
No break or placebo pills
Light or no menstruation
Spotting possible
Major limitation:
Compliance is critical
Must be taken at the same time daily
Progestin Only: Subdermal Implant (Nexplanon)
(Characteristics, Advantages Limitation)
Etonogestrel implant
Single rod under the skin of the upper arm
Releases progestin continuously
Provides contraception for 3 years
Advantages:
Extremely effective
Long-acting
Limitations:
Irregular bleeding is common
Must be inserted and removed by an HCP
Progestin Only: Depot Injection (DMPA)
(Characteristics, Advantages Limitation)
DMPA-IM: given every 12 weeks
DMPA-SC: given every 12 weeks
SC formulation is less painful and may be self-administered
Advantages:
Highly effective
Limitations:
Continuous suppression of estrogen → decreased bone density
Black Box Warning: not to use for >2 years
May take up to 1 year to regain fertility
Must return every 3 months for injections
What is emergency contraception
Used to prevent unwanted pregnancy after unprotected or inadequately protected sex.
Should be taken as soon as possible
Most effective within the first 72 hours
Still somewhat effective up to 5 days after intercourse according to the slides
Name the drugs used in emergency contraception and explain their mechanism of action
Levonorgestrel EC
Progestin-only
Examples/formulations:
Two-dose formulation: 0.75 mg × 2 tablets
Plan B One-Step: single 1.5 mg tablet
MOA:
Thickens cervical mucosa → impairs sperm transport
Impairs corpus luteum function
Inhibits fertilization
Ulipristal (Ella)
A selective progesterone receptor modulator (SPRM)
Has mixed progesterone agonist and antagonist properties
MOA:
Primary mechanism is listed as unknown
Consistently shown to inhibit ovulation
Other reported but debatable effects involve:
Fallopian tube motility
Fertilization
Implantation
Sperm function
Prescription only
Single dose taken within 120 hours after unprotected intercourse
Copper containing IUDs
Spermicidal action of copper
The progestin in combined hormonal contraceptive patch contains ______ and the pill contains ______.
Active metabolite
Prodrug
Food intake is regulated by what 3 organs?
Hypothalamus 2. Gut 3. Adipose tissue
Role of hypothalamus in food intake
Feeding Center
Neuron release:
1. Neuropeptide Y (NPY)+ Agouti-related peptide (AgRP)
2. Orexin
3. Melanin concentrating hormone (MCH)
Satiety Center
Neuron release:
1. Proopiomelanocortin (POMC: Endorphins + α MSH)
2.Cocaine & amphetamine regulated transcript (CART)
3. GLP-1
Role of GI Tract in food intake
Empty Stomach releases ghrelin to stimulate hypothalamus and to initiate hunger
After food intake & digestion → small intestine releases CCK, PYY, GLP-1, Insulin to act on satiety center in hypothalamus
Adipose tissue releases [] and satiety center to release [].
Leptin
POMC
Summary of Regulation of Feeding Behavior
Empty stomach
Ghrelin is released → stimulates the hypothalamus.
Hypothalamus releases NPY, Orexins, AgRP, and MCH.
Result: increased hunger and feeding behavior.
Feeding
The small intestine releases CCK, PYY, and GLP-1; insulin also increases.
Stimulate the hypothalamus to release POMC and CART.
Result: satiety
Leptin
Leptin is released from adipose tissue.
Stimulate the hypothalamus to release POMC and CART.
Result: increased satiety
Obesity Pharmacotherapy
Anti-obesity drugs that may be used for long-term
Peripherally acting drugs
Orlistat (Xenical, Alli)
Semaglutide (Wegovy), Orforglipron (Foundayo), Tirzepatide (Zepbound)
Centrally acting drugs
Phentermine-Topiramate (Qsymia)
Bupropion-Naltrexone (Contrave)
Anti-obesity drugs that can be used for short-term only
Phentermine
Orlistat (Xenical, Alli) MOA
Inhibits intestinal lipases via acylation at serine 152 of lipases

Name the drugs used in the management of obesity and describe their mechanism of action
Drug/Class | Molecular Target | Pharmacological Outcome | How It Reduces Obesity |
|---|---|---|---|
Orlistat | Intestinal lipases | Inhibits breakdown and absorption of dietary fat | ↓ Fat absorption → ↓ caloric intake |
GLP-1 analogs | GLP-1 receptors | ↑ Satiety, ↓ appetite, slows gastric emptying | Eat less due to increased fullness and reduced hunger |
Phentermine–Topiramate | Phentermine: ↑ norepinephrine; Topiramate: Multiple CNS pathways (including Na+ channels, Ca2+ channels, GABA/glutamate) | Suppresses appetite and increases satiety | ↓ Hunger and food cravings → ↓ caloric intake |
Bupropion–Naltrexone | Bupropion: dopamine/norepinephrine reuptake; Naltrexone: opioid receptors | Activates appetite-suppressing POMC neurons and prevents inhibitory feedback | ↓ Appetite and cravings → ↓ food intake |
Explain the pathophysiology of menorrhagia
Menorrhagia = heavy menstrual blood loss (>80 mL) or prolonged bleeding (>7 days).
Causes include:
Hematological causes
von Willebrand disease → impaired platelet adhesion
Thrombocytopenia → decreased platelets
Hepatic cirrhosis → impaired synthesis of coagulation factors
Uterine causes: fibroids, adenomyosis, polyps, cancer
Endocrine: hypothyroidism (rare)
The result is excessive menstrual bleeding, which can lead to anemia and hypovolemia, causing fatigue, lightheadedness, orthostasis, tachycardia, and pallor.
Explain the pathophysiology of dysmenorrhea
Dysmenorrhea = crampy pelvic pain occurring just before or with menstruation, usually lasting 1–3 days.
Primary dysmenorrhea
Occurs with normal pelvic anatomy:
Regressing corpus luteum → ↓ estrogen and progesterone → shedding of uterine lining + influx of inflammatory cells → production of prostaglandins (especially PGE₂ and PGF₂α) and leukotrienes.
Prostaglandins → uterine smooth muscle contraction and uterine ischemia → pain
Leukotrienes → stimulate nociceptive nerve endings → pain
Secondary dysmenorrhea
Occurs due to pelvic pathology, such as:
Cervical stenosis
Endometriosis
Pelvic infections
Polyps
Fibroids
Pelvic adhesions or outflow obstruction
Explain the pathophysiology of PMS;PMDD
The slides emphasize that estrogen and progesterone play an important role, since PMDD does not occur before menarche, during pregnancy, or after menopause.
Three interconnected theories:
Genetic susceptibility or increased sensitivity of certain brain structures/functions to hormonal changes.
Allopregnanolone, a progesterone metabolite, binds to GABA receptors and interferes with neurons containing the serotonin neurotransmitter.
Estrogen affects serotonin by interfering with its synthesis, metabolism, and autoreceptor-mediated release.
This helps explain the cyclic mood and physical symptoms associated with PMS/PMDD.
Mechanisms of Drugs Used for Menorrhagia
NSAIDs (ibuprofen, naproxen, mefenamic acid)
Inhibit cyclooxygenase (COX) → ↓ uterine prostaglandins → ↓ uterine inflammation and contractions → ↓ bleeding. Menstrual disorders Pathophysio…
Combined hormonal contraceptives (CHCs)
Estrogen inhibits FSH and LH through negative feedback.
Progestin induces cell differentiation.
Overall → inhibition of endometrial tissue proliferation → ↓ prostaglandins → ↓ bleeding. Menstrual disorders Pathophysio…
Levonorgestrel-releasing IUD
Sustained inhibition of endometrial proliferation → endometrial atrophy → less endometrial lining is shed → ↓ bleeding. Menstrual disorders Pathophysio…
Tranexamic acid
An antifibrinolytic and plasmin blocker:
Binds plasminogen and plasmin → prevents plasmin from binding and degrading fibrin → facilitates clotting → ↓ bleeding. Menstrual disorders Pathophysio…
GnRH receptor agonists
Initially: stimulate GnRH receptors → ↑ FSH and LH release
Continuous stimulation: receptor internalization/downregulation → shutdown of FSH and LH release → menstruation shuts down → ↓ bleeding
Mechanisms of Drugs Used for Dysmenorrhea
NSAIDs
Inhibit prostaglandin synthesis → less uterine contraction/inflammation → less pain.
Combined oral contraceptives
Inhibit endometrial tissue proliferation → ↓ prostaglandins and leukotrienes → less pain.
Levonorgestrel IUD and Depot Medroxyprogesterone Acetate (DMPA)
Cause endometrial atrophy and inhibit prostaglandin/leukotriene generation → less pain.
Explain the pathophysiology of polycystic ovarian syndrome (PCOS)
Main pathway:
↑ GnRH pulse frequency → ↑ LH + ↓ FSH
Increased LH:
↑ LH → increased testosterone synthesis in theca cells → hyperandrogenism
This causes:
Acne
Hirsutism
Baldness
Reduced FSH:
↓ FSH → ↓ estrogen → inhibition of folliculogenesis → no ovulation
Then:
No ovulation → no corpus luteum → lack of progesterone → accumulation of follicles containing unreleased ova → polycystic appearance of the ovaries + oligo/amenorrhea.
Other contributing causes include:
Increased CYP17 and 17-βHSD activity → ↑ testosterone synthesis
Insulin resistance/hyperinsulinemia → ↑ testosterone synthesis and ↓ sex hormone-binding protein → ↑ free testosterone
Obesity → promotes insulin resistance, hyperinsulinemia, and androgen formation Menstrual disorders Pathophysio…
Explain the pathophysiology of endometriosis
Endometriosis = presence of endometrial tissue outside the uterus in the peritoneum.
Possible mechanisms:
Retrograde flow theory
Menstrual fluid and endometrial tissue flow backward through the fallopian tubes into the peritoneal cavity.
Coelomic metaplasia theory
Residual embryonic cells or mesenchymal cells develop/transdifferentiate into endometrial cells, potentially mediated by autoimmune factors.
What causes the damage?
The ectopic endometrial tissue:
Responds to cyclic estrogen changes → bleeds when hormone levels drop → intraperitoneal blood causes WBC influx → chronic cycle of inflammation → ROS formation + lipid peroxidation + scar formation.
Endometrial tissue outside uterus → cyclic hormone response → bleeding → inflammation → ROS/scarring
Understand the regulation of feeding by hypothalamus and GI tract
Food intake is regulated mainly by hypothalamus, gut, adipose tissue through endocrine and neural signals.
Feeding center → Hunger | Satiety center → Fullness |
|---|---|
NPY | POMC |
AgRP | CART |
Orexin | GLP-1 |
MCH |
GI tract:
Empty stomach → ghrelin → hypothalamus → NPY, Orexin, AgRP, MCH → feeding behavior
After food intake and digestion, the small intestine releases:
CCK
PYY
GLP-1
Insulin
→ POMC and CART, resulting in satiety. Pharmacology of anti-obesity dr…
Adipose tissue releases leptin:
Leptin → hypothalamus → POMC/CART → satiety
Understand the impact of bariatric surgery on absorption of nutrients and drugs
Why does absorption change
↓ Stomach area
This can lead to:
↓ Food intake
↓ Dietary fat intake
↓ Micronutrient and vitamin intake
↓ Absorption of fat-soluble vitamins
↑ Stomach pH
This can cause:
↓ Calcium absorption
↓ Reduction of Fe³⁺ → Fe²⁺
Therefore, ↓ available Fe²⁺/iron absorption
Bypassing the duodenum (Roux-en-Y)
The duodenum is an important site for absorption. Bypassing it can decrease absorption of:
Iron
Vitamins
Micronutrients
Effects on Drug Absorption
↑ Stomach pH may affect drugs that depend on normal GI pH for release.
Enteric-coated drugs intended to release in the more basic intestine may be released differently.
Roux-en-Y bypasses the duodenum, reducing surface area for absorption.
This is especially important for extended-release drugs.
Name the drugs used in the management of obesity and describe their mechanism of action
Drug | Molecular Target | Pharmacological Outcome | How it reduces obesity |
|---|---|---|---|
Orlistat (Xenical, Alli) | Intestinal lipases | Inhibits lipase activity → prevents breakdown of triglycerides into free fatty acids | ↓ Digestion and absorption of dietary fat (also ↓ cholesterol absorption) |
GLP-1 analogs | GLP-1 receptors in GI tract and hypothalamus | Delays gastric emptying and suppresses appetite | ↑ Feeling of fullness + ↓ food intake/appetite |
Phentermine–Topiramate (Qsyima) | Phentermine: NE and dopamine neurotransmission; Topiramate: Na⁺/Ca²⁺ channels, GABA, glutamate pathways | Appetite suppression; topiramate may ↓ appetite and ↑ satiety | ↓ Appetite + ↑ satiety → ↓ food intake |
Bupropion–Naltrexone (Contrave) | Dopamine/NE pathways and POMC neurons; μ-opioid receptors | Activates POMC-mediated appetite suppression; naltrexone blocks negative feedback | Suppresses appetite → ↓ food intake |